John Fung to Immunosuppressive Agents
This is a "connection" page, showing publications John Fung has written about Immunosuppressive Agents.
Connection Strength
9.037
-
Limitations of current liver transplant immunosuppressive regimens: renal considerations. Hepatobiliary Pancreat Dis Int. 2017 Feb; 16(1):27-32.
Score: 0.404
-
Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. Transplantation. 2017 Feb; 101(2):341-349.
Score: 0.404
-
Future prospects in immunosuppression for liver transplantation. Liver Transpl. 2011 Nov; 17 Suppl 3:S54-9.
Score: 0.281
-
Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011 Nov; 17 Suppl 3:S1-9.
Score: 0.281
-
Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl. 2008 Jan; 14(1):46-52.
Score: 0.215
-
Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 2005 Mar; 11(3):267-80.
Score: 0.177
-
Tacrolimus and transplantation: a decade in review. Transplantation. 2004 May 15; 77(9 Suppl):S41-3.
Score: 0.167
-
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003 Sep 15; 76(5):827-32.
Score: 0.160
-
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003 Sep; 9(9):954-60.
Score: 0.159
-
Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation. Exp Clin Transplant. 2003 Jun; 1(1):48-55.
Score: 0.157
-
Tolerogenic immunosuppression for organ transplantation. Lancet. 2003 May 03; 361(9368):1502-10.
Score: 0.156
-
Rapamycin: friend, foe, or misunderstood? Liver Transpl. 2003 May; 9(5):469-72.
Score: 0.156
-
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002 Sep; 8(9):838-40.
Score: 0.149
-
The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 2002 Sep; 8(9):841-5.
Score: 0.149
-
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002 Jan; 8(1):40-6.
Score: 0.142
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001 Sep 27; 72(6):1091-7.
Score: 0.140
-
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 2001 Jul; 7(7):623-30.
Score: 0.137
-
Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001 Mar; 41(3):268-76.
Score: 0.134
-
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc. 2001 Feb-Mar; 33(1-2):1342-4.
Score: 0.133
-
Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc. 2000 May; 32(3):663-4.
Score: 0.127
-
Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord. 1999 Jun; 9(2):101-3.
Score: 0.119
-
Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg. 1999 Mar; 5(2):144-50.
Score: 0.117
-
Immunosuppressive therapy. Surg Clin North Am. 1999 Feb; 79(1):59-76.
Score: 0.116
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27; 66(10):1395-8.
Score: 0.115
-
Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg. 1998 Nov; 4(6):448-54.
Score: 0.114
-
Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression. Ann Transplant. 2018 Oct 26; 23:751-757.
Score: 0.114
-
Role of splenectomy in human liver transplantation under modern-day immunosuppression. Dig Dis Sci. 1998 Sep; 43(9):1931-7.
Score: 0.113
-
Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis. 1998 Jun; 31(6 Suppl 1):S7-14.
Score: 0.111
-
Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc. 1998 Jun; 30(4):1403-4.
Score: 0.111
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.110
-
Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation. 1998 Apr 27; 65(8):1140.
Score: 0.110
-
William Hunter Harridge lecture: The changing face of short-gut syndrome management. Am J Surg. 2017 Mar; 213(3):448-451.
Score: 0.101
-
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg. 1996 Aug; 183(2):117-25.
Score: 0.098
-
Impact of De Novo and Preexisting Inflammatory Bowel Disease on the Outcome of Orthotopic Liver Transplantation. Inflamm Bowel Dis. 2016 07; 22(7):1670-8.
Score: 0.097
-
FK506 in solid organ transplantation. Ther Drug Monit. 1995 Dec; 17(6):592-5.
Score: 0.093
-
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99(7):1455-62.
Score: 0.091
-
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation. 1994 Mar 27; 57(6):860-5.
Score: 0.083
-
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
Score: 0.082
-
State of immunosuppressive agents in organ transplantation. Transplant Proc. 1992 Dec; 24(6):2372-4.
Score: 0.076
-
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
Score: 0.067
-
Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant. 2010 Sep-Oct; 24(5):701-8.
Score: 0.065
-
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc. 1990 Feb; 22(1):52-6.
Score: 0.062
-
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22(1):6-12.
Score: 0.062
-
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation. 2006 Dec 27; 82(12):1621-4.
Score: 0.050
-
Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation. 2006 Dec 27; 82(12):1649-52.
Score: 0.050
-
Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus. J Heart Lung Transplant. 2006 Mar; 25(3):310-9.
Score: 0.047
-
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006 Jan 12; 354(2):141-50.
Score: 0.047
-
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6(5 Pt 2):1111-31.
Score: 0.047
-
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl. 2005 Nov; 11(11):1343-52.
Score: 0.046
-
Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation. 2005 Sep 27; 80(6):859-64.
Score: 0.046
-
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005 Apr; 200(4):505-15; quiz A59-61.
Score: 0.044
-
Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. Transplantation. 2005 Feb 27; 79(4):451-9.
Score: 0.044
-
Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation. 2004 Dec 15; 78(11):1683-8.
Score: 0.044
-
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004 Oct 15; 78(7):966-71.
Score: 0.043
-
Liver transplantation in patients with HIV infection. Liver Transpl. 2004 Oct; 10(10 Suppl 2):S39-53.
Score: 0.043
-
Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation. 2004 Mar 27; 77(6):897-902.
Score: 0.041
-
Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol. 2004 Feb 01; 172(3):1355-63.
Score: 0.041
-
De novo breast cancer in patients with liver transplantation: University of Pittsburgh's experience and review of the literature. Liver Transpl. 2004 Jan; 10(1):1-6.
Score: 0.041
-
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg. 2003 Oct; 238(4):520-5; discussion 525-7.
Score: 0.040
-
The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation. 2003 Apr 15; 75(7):1020-5.
Score: 0.039
-
Prolonged survival of heart allografts transduced with AAV-CTLA4Ig. Microsurgery. 2003; 23(5):489-93.
Score: 0.038
-
Administration of antisense oligodeoxyribonucleotides targeting NF-kappaB prolongs allograft survival via suppression of cytotoxicity. Microsurgery. 2003; 23(5):494-7.
Score: 0.038
-
Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc. 2002 Aug; 34(5):1540-1.
Score: 0.037
-
A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc. 2002 Aug; 34(5):1651-2.
Score: 0.037
-
Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001 Oct; 5(5):359-64.
Score: 0.035
-
Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 2001 Sep 15; 72(5):851-5.
Score: 0.035
-
Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001 Aug; 23(4):354-62.
Score: 0.035
-
Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 05 01; 106(5):997-1003.
Score: 0.034
-
Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation. 2001 Apr 27; 71(8):1102-6.
Score: 0.034
-
Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation. 2001 Jan 27; 71(2):267-71.
Score: 0.033
-
Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 2000 Sep 15; 70(5):760-4.
Score: 0.032
-
Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease. Transplant Proc. 2000 Aug; 32(5):1032-3.
Score: 0.032
-
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000 Jun 15; 69(11):2330-6.
Score: 0.032
-
Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000 Jan 27; 69(2):265-71.
Score: 0.031
-
Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27; 68(12):1851-4.
Score: 0.031
-
An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1999 Sep 15; 68(5):650-5.
Score: 0.030
-
Posttransplant diabetes in pediatric recipients on tacrolimus. Transplantation. 1999 Mar 15; 67(5):771.
Score: 0.029
-
A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999 Feb 15; 67(3):411-5.
Score: 0.029
-
Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Transplant Proc. 1999 Feb-Mar; 31(1-2):453.
Score: 0.029
-
Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc. 1999 Feb-Mar; 31(1-2):646-7.
Score: 0.029
-
Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc. 1999 Feb-Mar; 31(1-2):700-1.
Score: 0.029
-
A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999 Feb-Mar; 31(1-2):1134.
Score: 0.029
-
Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival. Transplant Proc. 1999 Feb-Mar; 31(1-2):1242-3.
Score: 0.029
-
Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
Score: 0.029
-
Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation. 1999 Jan 27; 67(2):266-72.
Score: 0.029
-
Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation. 1999 Jan 27; 67(2):299-303.
Score: 0.029
-
A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol. 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6.
Score: 0.029
-
Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998 Oct 27; 66(8):1047-52.
Score: 0.028
-
Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. Transplant Proc. 1998 Jun; 30(4):1091-2.
Score: 0.028
-
Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc. 1998 Jun; 30(4):1257-60.
Score: 0.028
-
Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1375-7.
Score: 0.028
-
Alopecia as a consequence of tacrolimus therapy. Transplantation. 1998 May 15; 65(9):1284.
Score: 0.028
-
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May; 186(5):512-25; discussion 525-7.
Score: 0.028
-
Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transplant Proc. 1998 Mar; 30(2):521.
Score: 0.027
-
Outcome of kidney transplantation in African-Americans using tacrolimus. Transplant Proc. 1997 Dec; 29(8):3731-2.
Score: 0.027
-
Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997 Sep; 29(6):2737-8.
Score: 0.026
-
Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997 Aug 27; 64(4):559-65.
Score: 0.026
-
Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):306.
Score: 0.025
-
Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):310.
Score: 0.025
-
Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc. 1997 Feb-Mar; 29(1-2):532-3.
Score: 0.025
-
High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1081-2.
Score: 0.025
-
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc. 1997 Feb-Mar; 29(1-2):1174-7.
Score: 0.025
-
Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation. 1997 Jan 27; 63(2):223-8.
Score: 0.025
-
Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997 Jan 27; 63(2):243-9.
Score: 0.025
-
"Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation. 1996 Nov 15; 62(9):1242-6.
Score: 0.025
-
Concomitant infusion of unmodified donor bone marrow into unconditioned recipients of intestinal allografts. Transplant Proc. 1996 Oct; 28(5):2757-8.
Score: 0.025
-
Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc. 1996 Aug; 28(4):2119-20.
Score: 0.024
-
Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation. 1996 Jun 27; 61(12):1730-5.
Score: 0.024
-
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995 Nov 18; 346(8986):1346-50.
Score: 0.023
-
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation. 1995 Jan 27; 59(2):212-7.
Score: 0.022
-
Cytidine potentiates the inhibitory effect of brequinar sodium on concordant cardiac xenograft rejection. Transplant Proc. 1994 Jun; 26(3):1288-9.
Score: 0.021
-
Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation. 1994 Jan; 57(1):149-51.
Score: 0.020
-
Cytidine potentiates the inhibitory effect of brequinar sodium on xeno-MLR, antibody production, and concordant hamster to rat cardiac xenograft survival. Ann N Y Acad Sci. 1993 Nov 30; 696:227-34.
Score: 0.020
-
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation. 1993 Mar; 55(3):659-61.
Score: 0.019
-
Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc. 1993 Feb; 25(1 Pt 1):781-3.
Score: 0.019
-
Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine. Transplant Proc. 1993 Feb; 25(1 Pt 1):704-5.
Score: 0.019
-
Infectious complications after human small bowel transplantation. Transplant Proc. 1992 Jun; 24(3):1249-50.
Score: 0.018
-
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc. 1991 Dec; 23(6):2957-8.
Score: 0.018
-
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3232-3.
Score: 0.018
-
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991 Aug; 110(2):357-63; discussion 363-4.
Score: 0.017
-
Patient participation in research among solid organ transplant recipients in the United States. Transplantation. 2011 Jun 27; 91(12):1424-35.
Score: 0.017
-
Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation. 1991 Apr; 51(4):913-5.
Score: 0.017
-
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc. 1991 Feb; 23(1 Pt 2):1108-10.
Score: 0.017
-
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991 Feb; 23(1 Pt 2):1397-402.
Score: 0.017
-
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc. 1991 Feb; 23(1 Pt 2):914-9.
Score: 0.017
-
Use of FK 506 in pediatric patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):924-7.
Score: 0.017
-
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
Score: 0.016
-
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
Score: 0.016
-
Transplantation. JAMA. 1990 May 16; 263(19):2686-7.
Score: 0.016
-
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet. 1990 Mar 17; 335(8690):674.
Score: 0.016
-
Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):106-9.
Score: 0.016
-
FK 506 dosage in human organ transplantation. Transplant Proc. 1990 Feb; 22(1):23-4.
Score: 0.016
-
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
Score: 0.016
-
The side effects of FK 506 in humans. Transplant Proc. 1990 Feb; 22(1):35-6.
Score: 0.016
-
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):41-3.
Score: 0.016
-
Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc. 1990 Feb; 22(1):44-6.
Score: 0.016
-
Assay of FK 506 in plasma. Transplant Proc. 1990 Feb; 22(1):50-1.
Score: 0.016
-
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990 Feb; 22(1):57-9.
Score: 0.016
-
Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):93-5.
Score: 0.016
-
Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005 Mar; 37(2):923-6.
Score: 0.011
-
Synergistic effect of cold and warm ischemia time on postoperative graft outcome in human liver transplantation. Hepatogastroenterology. 2004 Sep-Oct; 51(59):1413-6.
Score: 0.011
-
Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol. 2004 May; 28(5):658-69.
Score: 0.010
-
Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl. 2004 Feb; 10(2):253-63.
Score: 0.010
-
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003 Apr; 17(2):77-88.
Score: 0.010
-
Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int. 2003 May; 16(5):336-40.
Score: 0.010
-
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002 Sep 15; 169(6):3382-91.
Score: 0.009
-
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore). 2002 Sep; 81(5):333-48.
Score: 0.009
-
Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc. 2002 Aug; 34(5):1968-9.
Score: 0.009
-
Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol. 2001 Apr; 158(4):1379-90.
Score: 0.008
-
Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 2001 Feb-Mar; 33(1-2):1235-6.
Score: 0.008
-
Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. Transplant Proc. 2000 Dec; 32(8):2710-2.
Score: 0.008
-
The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival. Transplant Proc. 2000 Sep; 32(6):1197-8.
Score: 0.008
-
The long-term efficacy of multivisceral transplantation. Transplant Proc. 2000 Sep; 32(6):1219-20.
Score: 0.008
-
Loss of serum bicarbonate after discordant liver xenotransplantation. Transplant Proc. 2000 Aug; 32(5):1110.
Score: 0.008
-
A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 2000 Apr; 119(4 Pt 1):673-81.
Score: 0.008
-
Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg. 1999 Mar; 5(2):101-6.
Score: 0.007
-
Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl. 1999; 217-21.
Score: 0.007
-
Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998 Feb 27; 65(4):499-504.
Score: 0.007
-
Current status of intestinal transplantation in children. J Pediatr Surg. 1998 Feb; 33(2):243-54.
Score: 0.007
-
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998 Jan 15; 65(1):82-6.
Score: 0.007
-
Cardiac operations in solid-organ transplant recipients. Ann Thorac Surg. 1997 Nov; 64(5):1270-8.
Score: 0.007
-
Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997 Jul 27; 64(2):252-7.
Score: 0.007
-
Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997 Jul-Aug; 44(16):1172-81.
Score: 0.007
-
Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. Transplant Proc. 1997 Feb-Mar; 29(1-2):454-5.
Score: 0.006
-
Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. Transplant Proc. 1997 Feb-Mar; 29(1-2):700.
Score: 0.006
-
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc. 1996 Oct; 28(5):2959-65.
Score: 0.006
-
Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant Proc. 1996 Jun; 28(3):1229-34.
Score: 0.006
-
Daily serum inflammatory cytokine (tumor necrosis factor-alpha, interleukin-6) monitoring in liver transplantation focusing on allograft rejection: a five-case report. Transplant Proc. 1996 Jun; 28(3):1237-40.
Score: 0.006
-
Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):733-4.
Score: 0.006
-
Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. Transplant Proc. 1996 Apr; 28(2):735.
Score: 0.006
-
Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. Transplant Proc. 1996 Apr; 28(2):736-7.
Score: 0.006
-
Perioperative treatment with phosphatidic acid inhibitor (Lisofylline leads to prolonged survival of hearts in the guinea pig to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):738-9.
Score: 0.006
-
Small bowel transplantation: current progress and clinical application. Hepatogastroenterology. 1996 Mar-Apr; 43(8):363-76.
Score: 0.006
-
Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest. 1996 Jan 01; 97(1):217-25.
Score: 0.006
-
Two-year experience with FK 506 in pediatric patients. Transplant Proc. 1993 Feb; 25(1 Pt 1):619-21.
Score: 0.005
-
Liver transplantation under cyclosporine: a decade of experience. Transplant Proc. 1991 Feb; 23(1 Pt 2):1393-6.
Score: 0.004